Although people think melanoma is usually due to excessive solar UV irradiation. But the association between sun exposure and melanoma is not as simple as it looks. Exposure may be as important as the total amount of the form of ultraviolet radiation to shine on the skin. Time and exposure to the sun can change the form of opportunities for people suffering from melanoma.
Studies have shown that people who work outdoors and even some indoor work than have a lower risk of melanoma. The biggest risk seems to be from the intermittent sunlight and sunburn, and the use of sunbeds. Researchers are still trying to find out the reasons behind it. One view is that the skin is exposed to sunlight continued to produce adaptation, and better able to repair DNA damage caused by ultraviolet radiation. And another view melanin production increases are likely to form a protective shield against harmful rays. In addition, some studies have shown that melanoma and organic chlorides, heavy metals, drugs, and other environmental factors, including the related PCB.
According to the patient's genetic makeup tailored targeted therapies has become the cornerstone of treatment of advanced melanoma. There are some by targeting the immune system, enhance its ability to remove cancer drugs have also been entered into clinical practice. Patients have a limited number of available unresponsive several drugs are now showing a strong and lasting reaction. CUSABIO Human epidermal growth factor receptor ELISA Kit http://www.cusabio.com/html/product/CSB-E12124h.html can make sure the accurate and reliable of ELISA test results.
Over the years, clinicians are formed according to the organ to its cancer treatment, or the use of chemical drugs to kill rapidly proliferating cells to attack the cancer. But then the researchers will begin to discover the genetic mutation of normal cells into cancer cells. These findings reveal some of the mutant protein, the use of new drugs to block their oncologist can selectively target melanoma.
BRAF is an important weakness of melanoma researchers found. About two-thirds of melanoma BRAF protein-coding genes are minor changes occurred. Currently approved drugs targeting BRAF including Veronica sorafenib (Vemurafenib), Dara Phoenix (dabrafenib) and so on. Determining the activation of MAPK signaling pathway is the main reason after BRAF inhibitor resistance, MEK inhibitors such as imatinib Qumei (Trametinib) has become the treatment of advanced melanoma second main drugs. In addition to BRAF, NRAS mutated melanoma and eIF4F also drive drug development and an important factor.
The immunotherapy strategies include the use of the checkpoint inhibitors such as ipilimumab and other blocking effects of CTLA-4 protein in the immune system T cells to release the brakes. Or using PD-L1 and PD-1 targeting drugs to eliminate immune escape of cancer cells and the like.